Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription Articles published in Breast Cancer Retrieve available abstracts of 185 articles: HTML format

Single Articles

January 2022
1. YANG ZY, Yin SP, Ren Q, Lu DW, et al
   BAHD1 serves as a critical regulator of breast cancer cell proliferation and invasion.
   Breast Cancer. 2022 Jan 19. pii: 10.1007/s12282-022-01333.
   PubMed     Abstract available
   
   
   
2. ZENG Q, Lin X, Chen H, Yan Y, et al
   Multi-time scale transcriptomic analysis on the dynamic process of tamoxifen resistance development in breast cancer cell lines.
   Breast Cancer. 2022 Jan 18. pii: 10.1007/s12282-021-01325.
   PubMed     Abstract available
   
   
   
3. GU JH, He C, Zhao QY, Jiang TA, et al
   Usefulness of new shear wave elastography in early predicting the efficacy of neoadjuvant chemotherapy for patients with breast cancer: where and when to measure is optimal?
   Breast Cancer. 2022 Jan 17. pii: 10.1007/s12282-021-01327.
   PubMed     Abstract available
   
   
   
4. MORITA M, Shimomura A, Tokuda E, Horimoto Y, et al
   Is adjuvant chemotherapy necessary in older patients with breast cancer?
   Breast Cancer. 2022 Jan 15. pii: 10.1007/s12282-021-01329.
   PubMed     Abstract available
   
   
   
5. CARRETTI G, Mirandola D, Maestrini F, Sequi L, et al
   Quality of life improvement in breast cancer survivors affected by upper limb lymphedema through a novel multiperspective physical activity methodology: a monocentric pilot study.
   Breast Cancer. 2022 Jan 13. pii: 10.1007/s12282-021-01322.
   PubMed     Abstract available
   
   
   
6. UDDIN MN, Wang X
   Identification of key tumor stroma-associated transcriptional signatures correlated with survival prognosis and tumor progression in breast cancer.
   Breast Cancer. 2022 Jan 12. pii: 10.1007/s12282-022-01332.
   PubMed     Abstract available
   
   
   
7. ABDELRAZEK MA, Nageb A, Barakat LA, Abouzid A, et al
   BC-DETECT: combined detection of serum HE4 and TFF3 improves breast cancer diagnostic efficacy.
   Breast Cancer. 2022 Jan 7. pii: 10.1007/s12282-021-01328.
   PubMed     Abstract available
   
   
   
8. HAILEY V, Rojas-Garcia A, Kassianos AP
   A systematic review of behaviour change techniques used in interventions to increase physical activity among breast cancer survivors.
   Breast Cancer. 2022 Jan 6. pii: 10.1007/s12282-021-01323.
   PubMed     Abstract available
   
   
   
9. NIMBI FM, Magno S, Agostini L, Di Micco A, et al
   Sexuality in breast cancer survivors: sexual experiences, emotions, and cognitions in a group of women under hormonal therapy.
   Breast Cancer. 2022 Jan 6. pii: 10.1007/s12282-021-01320.
   PubMed     Abstract available
   
   
   
10. SUETA A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, et al
    Predictive and prognostic significance of BRCAness in HER2-negative breast cancer.
    Breast Cancer. 2022 Jan 5. pii: 10.1007/s12282-021-01319.
    PubMed     Abstract available
    
    
    November 2021
11. SU SY
    Nationwide mammographic screening and breast cancer mortality in Taiwan: an interrupted time-series analysis.
    Breast Cancer. 2021 Nov 26. pii: 10.1007/s12282-021-01315.
    PubMed     Abstract available
    
    
    
12. MUKAND NH, Ko NY, Nabulsi NA, Hubbard CC, et al
    The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women.
    Breast Cancer. 2021 Nov 19. pii: 10.1007/s12282-021-01309.
    PubMed     Abstract available
    
    
    
13. EVANS A, Sim YT, Lawson B, Macaskill J, et al
    The value of prognostic ultrasound features of breast cancer in different molecular subtypes with a focus on triple negative disease.
    Breast Cancer. 2021 Nov 15. pii: 10.1007/s12282-021-01311.
    PubMed     Abstract available
    
    
    
14. VAN EGDOM LSE, de Ligt KM, de Munck L, Koppert LB, et al
    Predictors of delayed breast reconstruction in the Netherlands: a 5-year follow-up study in stage I-III breast cancer patients.
    Breast Cancer. 2021 Nov 15. pii: 10.1007/s12282-021-01313.
    PubMed     Abstract available
    
    
    
15. WANG C, Lin Y, Zhu H, Zhou Y, et al
    Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis.
    Breast Cancer. 2021 Nov 11. pii: 10.1007/s12282-021-01312.
    PubMed     Abstract available
    
    
    
16. MAROUFI NF, Rashidi M, Vahedian V, Jahanbazi R, et al
    Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line.
    Breast Cancer. 2021 Nov 1. pii: 10.1007/s12282-021-01310.
    PubMed     Abstract available
    
    
    October 2021
17. VEGUNTA S, Bhatt AA, Choudhery SA, Pruthi S, et al
    Identifying women with increased risk of breast cancer and implementing risk-reducing strategies and supplemental imaging.
    Breast Cancer. 2021 Oct 19. pii: 10.1007/s12282-021-01298.
    PubMed     Abstract available
    
    
    
18. YOTSUMOTO D, Sagara Y, Kumamaru H, Niikura N, et al
    Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan.
    Breast Cancer. 2021 Oct 19. pii: 10.1007/s12282-021-01307.
    PubMed     Abstract available
    
    
    
19. TAKAHASHI M, Tokunaga E, Mori J, Tanizawa Y, et al
    Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Breast Cancer. 2021 Oct 18. pii: 10.1007/s12282-021-01295.
    PubMed     Abstract available
    
    
    
20. ROBERTS S, Rojas A, DiRaimo G, Orlando M, et al
    Defer surgery in operable breast cancer: how long is too long?
    Breast Cancer. 2021 Oct 18. pii: 10.1007/s12282-021-01302.
    PubMed     Abstract available
    
    
    
21. DIAZ-ROLDAN J, Eguia-Larrea M, Rubio-Sanchez T, Munoz-Bellvis L, et al
    Systematic review of synchronous contralateral axillary metastases in breast cancer: really M1 disease?
    Breast Cancer. 2021 Oct 15. pii: 10.1007/s12282-021-01293.
    PubMed     Abstract available
    
    
    
22. OZAKI A, Tachibana K, Ohtake T
    Correction to: Challenges and future directions in breast cancer care in Fukushima prefecture in Japan: correspondence to "A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Toho
    Breast Cancer. 2021 Oct 13. pii: 10.1007/s12282-021-01306.
    PubMed    
    
    
    
23. LI B, Cheng X, Zhu Y, Wan H, et al
    FOXA1 of regulatory variant associated with risk of breast cancer through allele-specific enhancer in the Chinese population.
    Breast Cancer. 2021 Oct 11. pii: 10.1007/s12282-021-01305.
    PubMed     Abstract available
    
    
    
24. LEBOK P, Bonte H, Kluth M, Moller-Koop C, et al
    6q deletion is frequent but unrelated to patient prognosis in breast cancer.
    Breast Cancer. 2021 Oct 8. pii: 10.1007/s12282-021-01301.
    PubMed     Abstract available
    
    
    
25. HORISAWA N, Adachi Y, Takatsuka D, Nozawa K, et al
    The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status.
    Breast Cancer. 2021 Oct 7. pii: 10.1007/s12282-021-01303.
    PubMed     Abstract available
    
    
    September 2021
26. NOGUCHI M, Inokuchi M, Yokoi-Noguchi M, Morioka E, et al
    The involvement of axillary reverse mapping nodes in patients with clinically node-negative breast cancer.
    Breast Cancer. 2021 Sep 30. pii: 10.1007/s12282-021-01300.
    PubMed     Abstract available
    
    
    
27. TAIRA N, Kashiwabara K, Tsurutani J, Kitada M, et al
    Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
    Breast Cancer. 2021 Sep 25. pii: 10.1007/s12282-021-01296.
    PubMed    
    
    
    
28. KOH SJ, Ohsumi S, Takahashi M, Fukuma E, et al
    Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analys
    Breast Cancer. 2021 Sep 25. pii: 10.1007/s12282-021-01299.
    PubMed    
    
    
    
29. KAMIYA S, Satake H, Hayashi Y, Ishigaki S, et al
    Features from MRI texture analysis associated with survival outcomes in triple-negative breast cancer patients.
    Breast Cancer. 2021 Sep 16. pii: 10.1007/s12282-021-01294.
    PubMed     Abstract available
    
    
    
30. XU J, Iwabuchi E, Miki Y, Kanai A, et al
    FE65 in breast cancer and its clinicopathological significance.
    Breast Cancer. 2021 Sep 8. pii: 10.1007/s12282-021-01291.
    PubMed     Abstract available
    
    
    
31. TAIRA N, Kashiwabara K, Tsurutani J, Kitada M, et al
    Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
    Breast Cancer. 2021 Sep 7. pii: 10.1007/s12282-021-01290.
    PubMed     Abstract available
    
    
    
32. TOKUNAGA E, Masuda T, Ijichi H, Tajiri W, et al
    Impact of serum vitamin D on the response and prognosis in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer. 2021 Sep 6. pii: 10.1007/s12282-021-01292.
    PubMed     Abstract available
    
    
    
33. MORI N, Abe H, Mugikura S, Miyashita M, et al
    Discriminating low-grade ductal carcinoma in situ (DCIS) from non-low-grade DCIS or DCIS upgraded to invasive carcinoma: effective texture features on ultrafast dynamic contrast-enhanced magnetic resonance imaging.
    Breast Cancer. 2021;28:1141-1153.
    PubMed     Abstract available
    
    
    
34. NAKASHIMA K, Uematsu T, Harada TL, Takahashi K, et al
    Can breast MRI and adjunctive Doppler ultrasound improve the accuracy of predicting pathological complete response after neoadjuvant chemotherapy?
    Breast Cancer. 2021;28:1120-1130.
    PubMed     Abstract available
    
    
    August 2021
35. KOH SJ, Ohsumi S, Takahashi M, Fukuma E, et al
    Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the globa
    Breast Cancer. 2021 Aug 31. pii: 10.1007/s12282-021-01283.
    PubMed     Abstract available
    
    
    
36. LAI J, Chen B, Li Y, Lin X, et al
    Integrated analysis of cell cycle-related genes in HR+/HER2- breast cancer.
    Breast Cancer. 2021 Aug 27. pii: 10.1007/s12282-021-01289.
    PubMed     Abstract available
    
    
    
37. BRANDS-APPELDOORN ATPM, Maaskant-Braat AJG, Janssen L, van Osch LADM, et al
    Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy.
    Breast Cancer. 2021 Aug 26. pii: 10.1007/s12282-021-01287.
    PubMed     Abstract available
    
    
    
38. SUZUKI Y, Wenwen W, Ohta T, Hayashi SI, et al
    Correction to: Molecular targeted drugs resistance impairs doublestrand break repair and sensitizes ERpositive breast cancer to PARP inhibitors.
    Breast Cancer. 2021 Aug 22. pii: 10.1007/s12282-021-01288.
    PubMed    
    
    
    
39. ZHU L, Pan JN, Qian Z, Ye WW, et al
    High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.
    Breast Cancer. 2021 Aug 17. pii: 10.1007/s12282-021-01286.
    PubMed     Abstract available
    
    
    
40. HAMADNEH L, Bahader M, Abuarqoub R, AlWahsh M, et al
    PI3K/AKT and MAPK1 molecular changes preceding matrix metallopeptidases overexpression during tamoxifen-resistance development are correlated to poor prognosis in breast cancer patients.
    Breast Cancer. 2021 Aug 9. pii: 10.1007/s12282-021-01277.
    PubMed     Abstract available
    
    
    
41. LEE DG, Schuetz JM, Lai AS, Burstyn I, et al
    Interactions between exposure to polycyclic aromatic hydrocarbons and xenobiotic metabolism genes, and risk of breast cancer.
    Breast Cancer. 2021 Aug 5. pii: 10.1007/s12282-021-01279.
    PubMed     Abstract available
    
    
    
42. HUANG SL, Huang ZC, Zhang CJ, Xie J, et al
    LncRNA SNHG5 promotes the glycolysis and proliferation of breast cancer cell through regulating BACH1 via targeting miR-299.
    Breast Cancer. 2021 Aug 5. pii: 10.1007/s12282-021-01281.
    PubMed     Abstract available
    
    
    
43. SUZUKI Y, Wenwen W, Ohta T, Hayashi SI, et al
    Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors.
    Breast Cancer. 2021 Aug 3. pii: 10.1007/s12282-021-01282.
    PubMed     Abstract available
    
    
    
44. ZARIFMAHMOUDI L, Aghaee A, Treglia G, Sadeghi R, et al
    Sentinel lymph node mapping in breast cancer patients following neoadjuvant chemotherapy: systematic review and meta-analysis about head to head comparison of cN0 and cN + patients.
    Breast Cancer. 2021 Aug 2. pii: 10.1007/s12282-021-01280.
    PubMed     Abstract available
    
    
    July 2021
45. QIAO Y, van Londen GJ, Brufsky JW, Poppenberg JT, et al
    Perceived physical fatigability improves after an exercise intervention among breast cancer survivors: a randomized clinical trial.
    Breast Cancer. 2021 Jul 30. pii: 10.1007/s12282-021-01278.
    PubMed     Abstract available
    
    
    
46. TAKAHASHI S, Fukui T, Nomizu T, Kakugawa Y, et al
    TP53 signature diagnostic system using multiplex reverse transcription-polymerase chain reaction system enables prediction of prognosis of breast cancer patients.
    Breast Cancer. 2021 Jul 24. pii: 10.1007/s12282-021-01250.
    PubMed     Abstract available
    
    
    
47. UEMOTO Y, Uchida M, Kondo N, Wanifuchi-Endo Y, et al
    Predictive factors for patients who need treatment for chronic post-surgical pain (CPSP) after breast cancer surgery.
    Breast Cancer. 2021 Jul 22. pii: 10.1007/s12282-021-01275.
    PubMed     Abstract available
    
    
    
48. GASTERATOS K, Morsi-Yeroyannis A, Vlachopoulos NC, Spyropoulou GA, et al
    Microsurgical techniques in the treatment of breast cancer-related lymphedema: a systematic review of efficacy and patient outcomes.
    Breast Cancer. 2021 Jul 12. pii: 10.1007/s12282-021-01274.
    PubMed     Abstract available
    
    
    
49. SANGHA MS, Baker R, Ahmed M
    Axillary dissection versus axillary observation for low risk, clinically node-negative invasive breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2021 Jul 9. pii: 10.1007/s12282-021-01273.
    PubMed     Abstract available
    
    
    
50. TOYODA Y, Katanoda K, Ishii K, Yamamoto H, et al
    Negative impact of the COVID-19 state of emergency on breast cancer screening participation in Japan.
    Breast Cancer. 2021 Jul 9. pii: 10.1007/s12282-021-01272.
    PubMed     Abstract available
    
    
    
51. GIORELLO MB, Matas A, Marenco P, Davies KM, et al
    CD1a- and CD83-positive dendritic cells as prognostic markers of metastasis development in early breast cancer patients.
    Breast Cancer. 2021 Jul 9. pii: 10.1007/s12282-021-01270.
    PubMed     Abstract available
    
    
    
52. PHAM TM, Nguyen DK, Pham HM, Le DC, et al
    Average lifespan shortened due to breast cancer in Australia, 1990-2015.
    Breast Cancer. 2021 Jul 8. pii: 10.1007/s12282-021-01271.
    PubMed     Abstract available
    
    
    
53. MINEMURA H, Takagi K, Sato A, Yamaguchi M, et al
    Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases.
    Breast Cancer. 2021;28:915-926.
    PubMed     Abstract available
    
    
    
54. TOZAKI M, Yabuuchi H, Goto M, Sasaki M, et al
    Effects of gadobutrol on background parenchymal enhancement and differential diagnosis between benign and malignant lesions in dynamic magnetic resonance imaging of the breast.
    Breast Cancer. 2021;28:927-936.
    PubMed     Abstract available
    
    
    
55. TENG X, Hayashida T, Murata T, Nagayama A, et al
    A transposon screen identifies enhancement of NF-kappaB pathway as a mechanism of resistance to eribulin.
    Breast Cancer. 2021;28:884-895.
    PubMed     Abstract available
    
    
    
56. TANAKA K, Masuda N, Hayashi N, Sagara Y, et al
    Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
    Breast Cancer. 2021;28:896-903.
    PubMed     Abstract available
    
    
    
57. XU C, Gu Z, Liu J, Lin X, et al
    Adenosquamous carcinoma of the breast: a population-based study.
    Breast Cancer. 2021;28:848-858.
    PubMed     Abstract available
    
    
    June 2021
58. AMIOKA A, Kadoya T, Sueoka S, Kobayashi Y, et al
    Correction to: Effect of Wnt5a on drug resistance in estrogen receptorpositive breast cancer.
    Breast Cancer. 2021 Jun 28. pii: 10.1007/s12282-021-01268.
    PubMed    
    
    
    
59. PARKS RM, Alfarsi LH, Green AR, Cheung KL, et al
    Biology of primary breast cancer in older women beyond routine biomarkers.
    Breast Cancer. 2021 Jun 24. pii: 10.1007/s12282-021-01266.
    PubMed     Abstract available
    
    
    
60. JOSHI A, Larkins S, Evans R, Moodley N, et al
    Use and impact of breast cancer survivorship care plans: a systematic review.
    Breast Cancer. 2021 Jun 19. pii: 10.1007/s12282-021-01267.
    PubMed     Abstract available
    
    
    
61. GHOREISHY SM, Aminianfar A, Benisi-Kohansal S, Azadbakht L, et al
    Association between dietary phytochemical index and breast cancer: a case-control study.
    Breast Cancer. 2021 Jun 13. pii: 10.1007/s12282-021-01265.
    PubMed     Abstract available
    
    
    
62. LIN Y, Xu Y, Wang C, Song Y, et al
    Loco-regional therapy and the risk of breast cancer-related lymphedema: a systematic review and meta-analysis.
    Breast Cancer. 2021 Jun 9. pii: 10.1007/s12282-021-01263.
    PubMed     Abstract available
    
    
    May 2021
63. AMIOKA A, Kadoya T, Sueoka S, Kobayashi Y, et al
    Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer.
    Breast Cancer. 2021 May 28. pii: 10.1007/s12282-021-01241.
    PubMed     Abstract available
    
    
    
64. INOKUCHI M, Kutomi G, Kijima Y, Sakai T, et al
    Correction to: The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition.
    Breast Cancer. 2021 May 19. pii: 10.1007/s12282-021-01256.
    PubMed    
    
    
    
65. YAMAUCHI C, Yoshimura M, Sekiguchi K, Hamamoto Y, et al
    Correction to: The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition.
    Breast Cancer. 2021 May 19. pii: 10.1007/s12282-021-01255.
    PubMed    
    
    
    
66. IWATA H, Saji S, Ikeda M, Inokuchi M, et al
    Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient.
    Breast Cancer. 2021 May 19. pii: 10.1007/s12282-021-01253.
    PubMed    
    
    
    
67. UEMATSU T, Nakashima K, Kikuchi M, Kubota K, et al
    Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition.
    Breast Cancer. 2021 May 19. pii: 10.1007/s12282-021-01251.
    PubMed    
    
    
    
68. WANG L, Li Q, Aushev VN, Neugut AI, et al
    PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
    Breast Cancer. 2021 May 18. pii: 10.1007/s12282-021-01261.
    PubMed     Abstract available
    
    
    
69. PEARSON A, Dhillon HM, Kiely BE
    Genitourinary symptoms in women with breast cancer: what do oncology health professionals think and do about them?
    Breast Cancer. 2021 May 11. pii: 10.1007/s12282-021-01260.
    PubMed     Abstract available
    
    
    
70. CHEN XQ, Zhang F, Xiao FH, Peng Y, et al
    Deciphering the nexus between the tumor immune microenvironment and DNA methylation in subgrouping estrogen receptor-positive breast cancer.
    Breast Cancer. 2021 May 8. pii: 10.1007/s12282-021-01262.
    PubMed     Abstract available
    
    
    
71. CHAO X, Tan W, Tsang JY, Tse GM, et al
    Clinicopathologic and genetic features of metaplastic breast cancer with osseous differentiation: a series of 6 cases.
    Breast Cancer. 2021 May 3. pii: 10.1007/s12282-021-01246.
    PubMed     Abstract available
    
    
    
72. VILLASCO A, Accomasso F, D'Alonzo M, Agnelli F, et al
    Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients.
    Breast Cancer. 2021 May 3. pii: 10.1007/s12282-021-01258.
    PubMed     Abstract available
    
    
    
73. MEHRAJ U, Qayoom H, Mir MA
    Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives.
    Breast Cancer. 2021;28:539-555.
    PubMed     Abstract available
    
    
    
74. AKASHI M, Yamaguchi R, Kusano H, Yamaguchi M, et al
    ER staining levels affect HER2 staining and heterogeneity.
    Breast Cancer. 2021;28:720-726.
    PubMed     Abstract available
    
    
    
75. ZHANG R, Gao P, Han Y, Zhang R, et al
    Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study.
    Breast Cancer. 2021;28:672-683.
    PubMed     Abstract available
    
    
    
76. JIA M, Liao N, Chen B, Zhang G, et al
    PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
    Breast Cancer. 2021;28:644-652.
    PubMed     Abstract available
    
    
    April 2021
77. HIRATA K, Narabayashi M, Hanai Y, Fukumoto K, et al
    Comparison of thoracic and abdominal deep inspiration breath holds in whole-breast irradiation for patients with left-sided breast cancer.
    Breast Cancer. 2021 Apr 28. pii: 10.1007/s12282-021-01259.
    PubMed     Abstract available
    
    
    
78. SHIMOI T, Nagai SE, Yoshinami T, Takahashi M, et al
    Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.
    Breast Cancer. 2021 Apr 22. pii: 10.1007/s12282-021-01252.
    PubMed    
    
    
    
79. ADACHI Y, Oze I, Sawaki M, Hattori M, et al
    Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer.
    Breast Cancer. 2021 Apr 22. pii: 10.1007/s12282-021-01245.
    PubMed     Abstract available
    
    
    
80. OZAKI A, Tachibana K, Ohtake T
    Challenges and future directions in breast cancer care in Fukushima prefecture in Japan: correspondence to "A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Tohoku region in Ja
    Breast Cancer. 2021 Apr 20. pii: 10.1007/s12282-021-01254.
    PubMed    
    
    
    
81. NAGASAKI E, Kudo R, Tamura M, Hayashi K, et al
    Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report.
    Breast Cancer. 2021 Apr 11. pii: 10.1007/s12282-021-01240.
    PubMed     Abstract available
    
    
    
82. KONISHI T, Fujiogi M, Michihata N, Morita K, et al
    Comparisons of postoperative outcomes after breast cancer surgery in patients with and without renal replacement therapy: a matched-pair cohort study using a Japanese nationwide inpatient database.
    Breast Cancer. 2021 Apr 10. pii: 10.1007/s12282-021-01248.
    PubMed     Abstract available
    
    
    
83. PAPPOT H, Baeksted CW, Nissen A, Knoop A, et al
    Clinical effects of assessing electronic patient-reported outcomes monitoring symptomatic toxicities during breast cancer therapy: a nationwide and population-based study.
    Breast Cancer. 2021 Apr 9. pii: 10.1007/s12282-021-01244.
    PubMed     Abstract available
    
    
    
84. ZHANG J, Tian Q, Zhang M, Wang H, et al
    Immune-related biomarkers in triple-negative breast cancer.
    Breast Cancer. 2021 Apr 9. pii: 10.1007/s12282-021-01247.
    PubMed     Abstract available
    
    
    
85. SONG C, Lowe VJ, Lee S
    Inhibition of Cdc20 suppresses the metastasis in triple negative breast cancer (TNBC).
    Breast Cancer. 2021 Apr 3. pii: 10.1007/s12282-021-01242.
    PubMed     Abstract available
    
    
    
86. FUTAMURA M, Oba M, Masuda N, Bando H, et al
    Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study).
    Breast Cancer. 2021 Apr 3. pii: 10.1007/s12282-021-01238.
    PubMed     Abstract available
    
    
    
87. TAKADA M, Tanaka G, Hashimoto H, Hirai Y, et al
    Practical approach to prevent COVID-19 infection at breast cancer screening.
    Breast Cancer. 2021 Apr 2. pii: 10.1007/s12282-021-01235.
    PubMed     Abstract available
    
    
    
88. INOUE K, Masuda N, Iwata H, Takahashi M, et al
    Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
    Breast Cancer. 2021 Apr 1. pii: 10.1007/s12282-021-01239.
    PubMed     Abstract available
    
    
    March 2021
89. NAHVIJOU A, Safari H, Ameri H
    Correction to: Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population.
    Breast Cancer. 2021 Mar 26. pii: 10.1007/s12282-021-01243.
    PubMed    
    
    
    
90. DU L, Tao X, Shen X
    Human umbilical cord mesenchymal stem cell-derived exosomes inhibit migration and invasion of breast cancer cells via miR-21-5p/ZNF367 pathway.
    Breast Cancer. 2021 Mar 26. pii: 10.1007/s12282-021-01218.
    PubMed     Abstract available
    
    
    
91. SASADA S, Masumoto N, Emi A, Kadoya T, et al
    Clinical effect of the pathological axillary assessment method in breast cancer without clinical nodal metastasis.
    Breast Cancer. 2021 Mar 19. pii: 10.1007/s12282-021-01236.
    PubMed     Abstract available
    
    
    
92. BARZGAR BAROUGH N, Sajjadian F, Jalilzadeh N, Shafaei H, et al
    Understanding breast cancer heterogeneity through non-genetic heterogeneity.
    Breast Cancer. 2021 Mar 15. pii: 10.1007/s12282-021-01237.
    PubMed     Abstract available
    
    
    
93. VINH-HUNG V, Everaert H, Gorobets O, Van Parijs H, et al
    Breast cancer preoperative (18)FDG-PET, overall survival prognostic separation compared with the lymph node ratio.
    Breast Cancer. 2021 Mar 10. pii: 10.1007/s12282-021-01234.
    PubMed     Abstract available
    
    
    
94. WANG LF, Eaglehouse YL, Poppenberg JT, Brufsky JW, et al
    Effects of a personal trainer-led exercise intervention on physical activity, physical function, and quality of life of breast cancer survivors.
    Breast Cancer. 2021 Mar 10. pii: 10.1007/s12282-020-01211.
    PubMed     Abstract available
    
    
    
95. TAN PY, Teng KT
    Role of dietary fat on obesity-related postmenopausal breast cancer: insights from mouse models and methodological considerations.
    Breast Cancer. 2021 Mar 9. pii: 10.1007/s12282-021-01233.
    PubMed     Abstract available
    
    
    
96. TAKAHASHI M, Inoue K, Mukai H, Yamanaka T, et al
    Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
    Breast Cancer. 2021 Mar 7. pii: 10.1007/s12282-021-01232.
    PubMed     Abstract available
    
    
    
97. NAHVIJOU A, Safari H, Ameri H
    Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population.
    Breast Cancer. 2021 Mar 5. pii: 10.1007/s12282-021-01230.
    PubMed     Abstract available
    
    
    
98. MCMULLEN ER, Skala SL, Gonzalez ME, Djomehri S, et al
    Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes.
    Breast Cancer. 2021;28:496-505.
    PubMed     Abstract available
    
    
    
99. MAEDA H, Hayashida T, Watanuki R, Kikuchi M, et al
    Predictors of invasive disease in patients preoperatively diagnosed with ductal carcinoma without stromal invasion, with breast magnetic resonance imaging (MRI) and ultrasound (US).
    Breast Cancer. 2021;28:398-404.
    PubMed     Abstract available
    
    
    
100. CORADINI D, Gambazza S, Oriana S, Ambrogi F, et al
     Gene expression profile of normal breast tissue and body mass index.
     Breast Cancer. 2021;28:488-495.
     PubMed     Abstract available
     
     
     
101. FILIPE MD, Simons JM, Moeliker L, Waaijer L, et al
     Patient-reported outcomes of ductoscopy procedures for pathologic nipple discharge.
     Breast Cancer. 2021;28:471-477.
     PubMed     Abstract available
     
     
     
102. VERDE F, Vigliar E, Romeo V, Campanino MR, et al
     Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): a challenging cytological diagnosis with hybrid PET/MRI staging and follow-up.
     Breast Cancer. 2021;28:527-532.
     PubMed     Abstract available
     
     
     
103. KUMARI K, Kumar S, Parida DK, Mishra SK, et al
     EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen.
     Breast Cancer. 2021;28:355-367.
     PubMed     Abstract available
     
     
     
104. GLASGOW A, Sechrist H, Bomeisl P, Gilmore H, et al
     Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
     Breast Cancer. 2021;28:321-328.
     PubMed     Abstract available
     
     
     
105. CARRARA GFA, Evangelista AF, Scapulatempo-Neto C, Abrahao-Machado LF, et al
     Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival.
     Breast Cancer. 2021;28:307-320.
     PubMed     Abstract available
     
     
     
106. ZHAO JM, An Q, Sun CN, Li YB, et al
     Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients.
     Breast Cancer. 2021;28:298-306.
     PubMed     Abstract available
     
     
     
107. VUKSANOVIC D, Sanmugarajah J, Lunn D, Sawhney R, et al
     Unmet needs in breast cancer survivors are common, and multidisciplinary care is underutilised: the Survivorship Needs Assessment Project.
     Breast Cancer. 2021;28:289-297.
     PubMed     Abstract available
     
     
     
108. ALATAWI Y, Hansen RA, Chou C, Qian J, et al
     The impact of cognitive impairment on survival and medication adherence among older women with breast cancer.
     Breast Cancer. 2021;28:277-288.
     PubMed     Abstract available
     
     
     February 2021
109. KUREBAYASHI J, Shiba E, Toyama T, Matsumoto H, et al
     A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-respons
     Breast Cancer. 2021 Feb 27. pii: 10.1007/s12282-020-01205.
     PubMed     Abstract available
     
     
     
110. KURODA H, Jamiyan T, Yamaguchi R, Kakumoto A, et al
     Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer.
     Breast Cancer. 2021 Feb 25. pii: 10.1007/s12282-021-01227.
     PubMed     Abstract available
     
     
     
111. KAWATE T, Yoshida A, Sugae S, Asaga S, et al
     Recommendations for the management of breast cancer patients during the COVID-19 pandemic from the Japan Breast Cancer Society.
     Breast Cancer. 2021 Feb 20. pii: 10.1007/s12282-020-01214.
     PubMed     Abstract available
     
     
     
112. OHARA A, Naoi Y, Shimoda M, Tanei T, et al
     Impact of tumor cellularity on the HER2 amplification assay by OncoScan in breast cancer.
     Breast Cancer. 2021 Feb 16. pii: 10.1007/s12282-021-01226.
     PubMed     Abstract available
     
     
     
113. PARK S, Jeong J, Han W, Lee YJ, et al
     Is mastectomy with immediate reconstruction safe for patients undergoing neoadjuvant chemotherapy? A nationwide study from Korean Breast Cancer Society.
     Breast Cancer. 2021 Feb 14. pii: 10.1007/s12282-021-01223.
     PubMed     Abstract available
     
     
     
114. ZHANG Y, Tian J, Qu C, Peng Y, et al
     Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells.
     Breast Cancer. 2021 Feb 10. pii: 10.1007/s12282-021-01221.
     PubMed     Abstract available
     
     
     
115. OCHI T, Tsunoda H, Matsuda N, Nozaki F, et al
     Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
     Breast Cancer. 2021 Feb 9. pii: 10.1007/s12282-021-01220.
     PubMed     Abstract available
     
     
     
116. QUI S, Takeshita T, Sueta A, Tomiguchi M, et al
     Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum.
     Breast Cancer. 2021 Feb 4. pii: 10.1007/s12282-020-01212.
     PubMed     Abstract available
     
     
     January 2021
117. TANAKA Y, Ohno T, Kadonaga T, Kidokoro Y, et al
     Podoplanin expression in cancer-associated fibroblasts predicts unfavorable prognosis in node-negative breast cancer patients with hormone receptor-positive/HER2 - negative subtype.
     Breast Cancer. 2021 Jan 22. pii: 10.1007/s12282-021-01217.
     PubMed     Abstract available
     
     
     
118. OHNUKI K, Tohno E, Tsunoda H, Uematsu T, et al
     Correction to: Overall assessment system of combined mammography and ultrasound for breast cancer screening in Japan.
     Breast Cancer. 2021 Jan 21. pii: 10.1007/s12282-021-01216.
     PubMed    
     
     
     
119. LIU X, Chang Q, Wang H, Qian H, et al
     Discovery and function exploration of microRNA-155 as a molecular biomarker for early detection of breast cancer.
     Breast Cancer. 2021 Jan 21. pii: 10.1007/s12282-021-01215.
     PubMed     Abstract available
     
     
     
120. SONG BI
     A machine learning-based radiomics model for the prediction of axillary lymph-node metastasis in breast cancer.
     Breast Cancer. 2021 Jan 17. pii: 10.1007/s12282-020-01202.
     PubMed     Abstract available
     
     
     
121. CHEN Y, Noma S, Taguchi Y, Takahashi M, et al
     Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan.
     Breast Cancer. 2021 Jan 16. pii: 10.1007/s12282-020-01207.
     PubMed     Abstract available
     
     
     
122. HSUEH EJ, Loh EW, Lin JJ, Tam KW, et al
     Effects of yoga on improving quality of life in patients with breast cancer: a meta-analysis of randomized controlled trials.
     Breast Cancer. 2021 Jan 15. pii: 10.1007/s12282-020-01209.
     PubMed     Abstract available
     
     
     
123. SHIRDARREH M, Pezo RC
     Impact of obesity on clinical outcomes in hormone receptor-positive breast cancer: a systematic review.
     Breast Cancer. 2021 Jan 11. pii: 10.1007/s12282-020-01213.
     PubMed     Abstract available
     
     
     
124. NEDELJKOVIC M, Tanic N, Prvanovic M, Milovanovic Z, et al
     Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
     Breast Cancer. 2021 Jan 8. pii: 10.1007/s12282-020-01210.
     PubMed     Abstract available
     
     
     
125. CAO W, Jiang Y, Ji X, Ma L, et al
     An immune-related risk gene signature predicts the prognosis of breast cancer.
     Breast Cancer. 2021 Jan 5. pii: 10.1007/s12282-020-01201.
     PubMed     Abstract available
     
     
     
126. YEN TWF, Garacci Z, Laud PW, Pezzin LE, et al
     Guideline-concordant treatment predicts survival: a National Cancer Database validation study of novel composite locoregional and systemic treatment scores among women with early stage breast cancer.
     Breast Cancer. 2021 Jan 4. pii: 10.1007/s12282-020-01206.
     PubMed     Abstract available
     
     
     
127. OEI SL, Thronicke A, Matthes H, Schad F, et al
     Assessment of integrative non-pharmacological interventions and quality of life in breast cancer patients using real-world data.
     Breast Cancer. 2021 Jan 3. pii: 10.1007/s12282-020-01193.
     PubMed     Abstract available
     
     
     
128. MIYAKE T, Shimoda M, Tanei T, Kagara N, et al
     Sentinel lymph node biopsy after introducing Twirl(R) breast markers into suspicious lymph nodes in breast cancer patients.
     Breast Cancer. 2021 Jan 3. pii: 10.1007/s12282-020-01195.
     PubMed     Abstract available
     
     
     
129. YAMAGUCHI K, Hara Y, Kitano I, Hamamoto T, et al
     Relationship between MRI findings and invasive breast cancer with podoplanin-positive cancer-associated fibroblasts.
     Breast Cancer. 2021 Jan 3. pii: 10.1007/s12282-020-01198.
     PubMed     Abstract available
     
     
     
130. WANG H, Zhang S, Yee D, Basu S, et al
     Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis.
     Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01194.
     PubMed     Abstract available
     
     
     
131. CHEN J, Zhang X, Lu Y, Zhang T, et al
     Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
     Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01196.
     PubMed     Abstract available
     
     
     
132. YOKOE T, Kurozumi S, Nozawa K, Ozaki Y, et al
     Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
     Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01192.
     PubMed     Abstract available
     
     
     
133. FUJISAWA F, Kunimasa K, Kano-Fujiwara R, Sato Y, et al
     STK11 loss drives rapid progression in a breast cancer patient resulting in pulmonary tumor thrombotic microangiopathy.
     Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01200.
     PubMed     Abstract available
     
     
     
134. OHNUKI K, Tohno E, Tsunoda H, Uematsu T, et al
     Overall assessment system of combined mammography and ultrasound for breast cancer screening in Japan.
     Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01203.
     PubMed     Abstract available
     
     
     
135. MICHA AE, Sinnett V, Downey K, Allen S, et al
     Patient and clinician satisfaction and clinical outcomes of Magseed compared with wire-guided localisation for impalpable breast lesions.
     Breast Cancer. 2021;28:196-205.
     PubMed     Abstract available
     
     
     
136. YAGHOUBI S, Gharibi T, Karimi MH, Sadeqi Nezhad M, et al
     Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
     Breast Cancer. 2021;28:216-225.
     PubMed     Abstract available
     
     
     
137. WEI Y, Li H, Qu Q
     miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers.
     Breast Cancer. 2021;28:175-186.
     PubMed     Abstract available
     
     
     
138. ZHAO H
     The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
     Breast Cancer. 2021;28:187-195.
     PubMed     Abstract available
     
     
     
139. BOLAND MR, Nugent T, Nolan J, O'Mahony J, et al
     Fibromatosis of the breast: a 10-year multi-institutional experience and review of the literature.
     Breast Cancer. 2021;28:168-174.
     PubMed     Abstract available
     
     
     
140. ZHAO W, Tian Q, Zhao A, Wang B, et al
     The role of adjuvant radiotherapy in patients with malignant phyllodes tumor of the breast: a propensity-score matching analysis.
     Breast Cancer. 2021;28:110-118.
     PubMed     Abstract available
     
     
     
141. NAHVIJOU A, Safari H, Yousefi M, Rajabi M, et al
     Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.
     Breast Cancer. 2021;28:130-136.
     PubMed     Abstract available
     
     
     
142. SECOMBE KR, Ball IA, Shirren J, Wignall AD, et al
     Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.
     Breast Cancer. 2021;28:99-109.
     PubMed     Abstract available
     
     
     December 2020
143. SHAFEI MA, Flemban A, Daly C, Kendrick P, et al
     Differential expression of the BCAT isoforms between breast cancer subtypes.
     Breast Cancer. 2020 Dec 24. pii: 10.1007/s12282-020-01197.
     PubMed     Abstract available
     
     
     November 2020
144. MU G, Ji H, He H, Wang H, et al
     Immune-related gene data-based molecular subtyping related to the prognosis of breast cancer patients.
     Breast Cancer. 2020 Nov 27. pii: 10.1007/s12282-020-01191.
     PubMed     Abstract available
     
     
     
145. WANG B, Yan T, Sun L, Zhang G, et al
     A history of severe nausea and vomiting during pregnancy predicts a higher incidence of postoperative nausea and vomiting after breast cancer surgery without breast reconstruction.
     Breast Cancer. 2020 Nov 26. pii: 10.1007/s12282-020-01190.
     PubMed     Abstract available
     
     
     
146. WU X, Zhang X, Hao Y, Li J, et al
     Obesity-related protein biomarkers for predicting breast cancer risk: an overview of systematic reviews.
     Breast Cancer. 2020 Nov 25. pii: 10.1007/s12282-020-01182.
     PubMed     Abstract available
     
     
     
147. SAWAKI M, Yamada A, Kumamaru H, Miyata H, et al
     Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan.
     Breast Cancer. 2020 Nov 21. pii: 10.1007/s12282-020-01188.
     PubMed     Abstract available
     
     
     
148. KAWADA K, Taira N, Mizoo T, Suzuki Y, et al
     Relationships of physical and breast cancer phenotypes with three single-nucleotide polymorphisms (rs2046210, rs3757318, and rs3803662) associated with breast cancer risk in Japanese women.
     Breast Cancer. 2020 Nov 13. pii: 10.1007/s12282-020-01185.
     PubMed     Abstract available
     
     
     
149. NOGUCHI M, Inokuchi M, Noguchi M, Morioka E, et al
     Axillary surgery for breast cancer: past, present, and future.
     Breast Cancer. 2020 Nov 9. pii: 10.1007/s12282-020-01120.
     PubMed     Abstract available
     
     
     
150. BAN K, Tsunoda H, Togashi S, Kawaguchi Y, et al
     Breast cancer screening using digital breast tomosynthesis compared to digital mammography alone for Japanese women.
     Breast Cancer. 2020 Nov 9. pii: 10.1007/s12282-020-01180.
     PubMed     Abstract available
     
     
     
151. YU X, Guo J, Zhou Q, Huang W, et al
     A novel immune-related prognostic index for predicting breast cancer overall survival.
     Breast Cancer. 2020 Nov 4. pii: 10.1007/s12282-020-01175.
     PubMed     Abstract available
     
     
     
152. TANG L, Ma Z, Ishikawa Y, Matsushita H, et al
     Effect of radiotherapy after breast-conserving surgery in elderly patients with early breast cancer according to the AJCC 8th Edition Breast Cancer Staging System in Japan.
     Breast Cancer. 2020 Nov 3. pii: 10.1007/s12282-020-01181.
     PubMed     Abstract available
     
     
     October 2020
153. PRIYADARSHINI R, Raj GM, Sundaram R, Kayal S, et al
     Association of plasma docetaxel levels with ABCB1 gene polymorphisms and tumour response in locally advanced breast cancer patients of South India on neo-adjuvant chemotherapy.
     Breast Cancer. 2020 Oct 30. pii: 10.1007/s12282-020-01177.
     PubMed     Abstract available
     
     
     
154. SAKAMOTO N, Nashimoto M, Nakagawa M, Haruyama Y, et al
     Skin grafting utilizing a skin of lateral thoracic area for chest wall reconstruction in patient who underwent mastectomy for locally advanced breast cancer.
     Breast Cancer. 2020 Oct 30. pii: 10.1007/s12282-020-01173.
     PubMed     Abstract available
     
     
     
155. SHIMA H, Okuno T, Nakamura T, Noro A, et al
     Comparing the extent of breast cancer tumors through contrast-enhanced ultrasound vs B-mode, opposed with pathology: evergreen study.
     Breast Cancer. 2020 Oct 29. pii: 10.1007/s12282-020-01176.
     PubMed     Abstract available
     
     
     
156. PENG R, Cao J, Guo Q, Sun Q, et al
     Variant in BCAR4 gene correlated with the breast cancer susceptibility and mRNA expression of lncRNA BCAR4 in Chinese Han population.
     Breast Cancer. 2020 Oct 28. pii: 10.1007/s12282-020-01174.
     PubMed     Abstract available
     
     
     
157. LIAN B, Li H, Liu Y, Chai D, et al
     Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer.
     Breast Cancer. 2020 Oct 27. pii: 10.1007/s12282-020-01179.
     PubMed     Abstract available
     
     
     
158. MASUDA N, Mukai H, Inoue K, Rai Y, et al
     Analysis of subsequent therapy in Japanese patients with hormone receptorpositive/human epidermal growth factor receptor 2negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
     Breast Cancer. 2020 Oct 21. pii: 10.1007/s12282-020-01162.
     PubMed     Abstract available
     
     
     
159. LIANG H, Zhou G, Lv L, Lu J, et al
     KRAS expression is a prognostic indicator and associated with immune infiltration in breast cancer.
     Breast Cancer. 2020 Oct 16. pii: 10.1007/s12282-020-01170.
     PubMed     Abstract available
     
     
     
160. LING Y, Cao Q, Liu Y, Zhao J, et al
     Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
     Breast Cancer. 2020 Oct 12. pii: 10.1007/s12282-020-01169.
     PubMed     Abstract available
     
     
     
161. LAO C, Kuper-Hommel M, Elwood M, Campbell I, et al
     Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
     Breast Cancer. 2020 Oct 12. pii: 10.1007/s12282-020-01171.
     PubMed     Abstract available
     
     
     
162. HSU YH, Chen VC, Hsieh CC, Weng YP, et al
     Subjective and objective cognitive functioning among patients with breast cancer: effects of chemotherapy and mood symptoms.
     Breast Cancer. 2020 Oct 8. pii: 10.1007/s12282-020-01168.
     PubMed     Abstract available
     
     
     September 2020
163. BANDEIRA G, Rocha K, Lazar M, Ezquina S, et al
     Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer.
     Breast Cancer. 2020 Sep 28. pii: 10.1007/s12282-020-01165.
     PubMed     Abstract available
     
     
     
164. ONISHI N, Kataoka M
     Breast cancer screening for women at high risk: review of current guidelines from leading specialty societies.
     Breast Cancer. 2020 Sep 21. pii: 10.1007/s12282-020-01157.
     PubMed     Abstract available
     
     
     
165. AHMED M
     Optimizing breast cancer surgery during the COVID-19 pandemic.
     Breast Cancer. 2020 Sep 18. pii: 10.1007/s12282-020-01160.
     PubMed     Abstract available
     
     
     
166. FUJII T, Ichiba K, Honda C, Tokuda S, et al
     Prospective observational study of chemotherapy-induced alopecia after sequential FEC + taxane and the effects of age in breast cancer patients.
     Breast Cancer. 2020 Sep 17. pii: 10.1007/s12282-020-01161.
     PubMed     Abstract available
     
     
     
167. AHMED M
     Beyond the speed of SOUND.
     Breast Cancer. 2020;27:793-795.
     PubMed     Abstract available
     
     
     
168. TOMITA M, Oura S, Nishiguchi H, Makimoto S, et al
     A case of bilateral methotrexate-associated diffuse large B-cell lymphomas of the breasts with unique clinical presentation and outcome.
     Breast Cancer. 2020;27:1038-1043.
     PubMed     Abstract available
     
     
     
169. YAMAGUCHI M, Takagi K, Sato A, Miki Y, et al
     Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance.
     Breast Cancer. 2020;27:919-928.
     PubMed     Abstract available
     
     
     
170. IIDA M, Toyosawa D, Nakamura M, Tsuboi K, et al
     Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
     Breast Cancer. 2020;27:963-972.
     PubMed     Abstract available
     
     
     
171. JAMIYAN T, Kuroda H, Yamaguchi R, Nakazato Y, et al
     Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast.
     Breast Cancer. 2020;27:880-892.
     PubMed     Abstract available
     
     
     
172. CHOI H, Noh H, Cho IJ, Lim ST, et al
     Changes in neutrophil to lymphocyte ratio (NLR) during neoadjuvant treatment correlated with patients' survival.
     Breast Cancer. 2020;27:871-879.
     PubMed     Abstract available
     
     
     
173. CORADINI D, Gambazza S, Oriana S, Ambrogi F, et al
     Body mass index and gamma-glutamyl transferase expression in normal and cancerous breast tissue.
     Breast Cancer. 2020;27:850-860.
     PubMed     Abstract available
     
     
     July 2020
174. ADACHI Y, Okumura S, Sawaki M, Hattori M, et al
     Effects of neoadjuvant chemotherapy on operative adverse events and chemotherapy and radiotherapy in patients undergoing immediate breast reconstruction.
     Breast Cancer. 2020;27:716-723.
     PubMed     Abstract available
     
     
     
175. CHANG YK, Chen CT, Wang M, Yang Y, et al
     Could ductoscopy alleviate the need of microdochectomy in pathological nipple discharge?
     Breast Cancer. 2020;27:607-612.
     PubMed     Abstract available
     
     
     
176. ZAHA H, Motonari T, Abe N, Unesoko M, et al
     Fat necrosis in level I oncoplastic breast-conserving surgery focusing on a modified round block technique.
     Breast Cancer. 2020;27:567-572.
     PubMed     Abstract available
     
     
     May 2020
177. REINDERS FCJ, Young-Afat DA, Batenburg MCT, Bruekers SE, et al
     Higher reconstruction failure and less patient-reported satisfaction after post mastectomy radiotherapy with immediate implant-based breast reconstruction compared to immediate autologous breast reconstruction.
     Breast Cancer. 2020;27:435-444.
     PubMed     Abstract available
     
     
     
178. OKAMOTO S, Chen ST, Covelli JD, DeMartini WB, et al
     High-risk lesions diagnosed at MRI-guided vacuum-assisted breast biopsy: imaging characteristics, outcome of surgical excision or imaging follow-up.
     Breast Cancer. 2020;27:405-414.
     PubMed     Abstract available
     
     
     
179. VAN EGDOM LSE, de Kock MA, Apon I, Mureau MAM, et al
     Patient-Reported Outcome Measures may optimize shared decision-making for cancer risk management in BRCA mutation carriers.
     Breast Cancer. 2020;27:426-434.
     PubMed     Abstract available
     
     
     March 2020
180. VURAL V, Yilmaz OC
     The Turkish SentiMAG feasibility trial: preliminary results.
     Breast Cancer. 2020;27:261-265.
     PubMed     Abstract available
     
     
     
181. WADASADAWALA T, Sinha S, Parmar V, Verma S, et al
     Comparison of subjective, objective and patient-reported cosmetic outcomes between accelerated partial breast irradiation and whole breast radiotherapy: a prospective propensity score-matched pair analysis.
     Breast Cancer. 2020;27:206-212.
     PubMed     Abstract available
     
     
     
182. SOROR T, Lancellotta V, Kovacs G, Lanzotti V, et al
     kOBCS((c)): a novel software calculator program of the Objective Breast Cosmesis Scale (OBCS).
     Breast Cancer. 2020;27:179-185.
     PubMed     Abstract available
     
     
     January 2020
183. IZUMORI A, Kokubu Y, Sato K, Gomi N, et al
     Usefulness of second-look ultrasonography using anatomical breast structures as indicators for magnetic resonance imaging-detected breast abnormalities.
     Breast Cancer. 2020;27:129-139.
     PubMed     Abstract available
     
     
     
184. YOU C, Zhang Y, Gu Y, Xiao Q, et al
     Comparison of the diagnostic performance of synthesized two-dimensional mammography and full-field digital mammography alone or in combination with digital breast tomosynthesis.
     Breast Cancer. 2020;27:47-53.
     PubMed     Abstract available
     
     
     
185. NAGURA N, Hayashi N, Takei J, Yoshida A, et al
     Breast reconstruction after risk-reducing mastectomy in BRCA mutation carriers.
     Breast Cancer. 2020;27:70-76.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: